Table 1.

Cohort Characteristics Among Pre-Menopausal Women With NAFLD (n=207)

Age, median years (IQR)	35 (29-41)
Race, n (%)
White	150 (72.5)
Asian	13 (6.3)
Black	9 (4.4)
Hispanic, n (%)	52 (25.1)
Body mass index (BMI), median kg/cm2 (IQR)	36.4 (31.8-41.2)
Obesity (BMI ≥ 30 kg/cm2), n (%)	167 (80.7)
Waist circumference, median cm (IQR)	112 (99-120)
Abdominal adiposity (waist > 88cm), n (%)	192 (92.8)
Hypertension, n (%)	65 (31.4)
Total cholesterol, median mg/dL (IQR)	190 (167-215)
HDL, median mg/dL (IQR)	42 (35-50)
LDL, median mg/dL (IQR)	117 (94-138)
Triglycerides, median mg/dL (IQR)	146 (115-196)
Dyslipidemia	198 (95.7)
Type 2 diabetes, n (%)	67 (32.4)
HOMA-IR, median mg/dL (IQR)	4.6 (2.8-8.0)
Polycystic ovary syndrome (PCOS), self-report, n (%)	43 (20.8)
Total testosterone, median pg/mL (IQR)	210 (120-290)
Free testosterone (Free T), median pg/mL (IQR)*	2.8 (1.6-4.8)
Sex hormone binding globulin, median nmol/L (IQR)	37.8 (24.9-62.9)
NASH (borderline or definite), n (%)	144 (69.6)
NAFLD Activity Score, median (IQR)	4 (3-6)
NAFLD Activity Score among those with NASH	5 (4-7)
Any fibrosis, n (%)	140 (67.6)
Any fibrosis among those with NASH	131 (91.0)
Advanced fibrosis (stages 3-4), n (%)	31 (15.0)
Advanced fibrosis among those with NASH	30 (20.8)

^*Normal range for pre-menopausal populations 0.6-9.8pg/mL17